-
Je něco špatně v tomto záznamu ?
Sequential Treatment with Bevacizumab and Aflibercept for Metastatic Colorectal Cancer in Real-World Clinical Practice
T. Buchler, I. Kiss, J. Hornova, O. Fiala, M. Wiesnerova, M. Svoboda, J. Silar, K. Kopeckova, A. Poprach, J. Finek, L. Petruzelka, B. Melichar,
Jazyk angličtina Země Francie
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
ProQuest Central
od 2006-01-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2006-01-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest)
od 2006-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 2006-01-01 do Před 1 rokem
Family Health Database (ProQuest)
od 2006-01-01 do Před 1 rokem
- MeSH
- bevacizumab farmakologie terapeutické užití MeSH
- doba přežití bez progrese choroby MeSH
- dospělí MeSH
- kolorektální nádory farmakoterapie MeSH
- lidé středního věku MeSH
- lidé MeSH
- metastázy nádorů MeSH
- protokoly protinádorové kombinované chemoterapie farmakologie terapeutické užití MeSH
- receptory vaskulárního endoteliálního růstového faktoru terapeutické užití MeSH
- rekombinantní fúzní proteiny farmakologie terapeutické užití MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
BACKGROUND: Bevacizumab and aflibercept are currently the mainstay of antiangiogenic therapy for metastatic colorectal carcinoma (mCRC). They are often used in sequence with first- and second-line chemotherapy, especially in patients with RAS-mutated tumours. OBJECTIVE: The aim of the present study was to investigate the outcomes of patients with mCRC treated with the bevacizumab-aflibercept sequence in real-world clinical practice. PATIENTS AND METHODS: Data from a national clinical registry of targeted therapies for mCRC were analysed retrospectively. Overall, there were 366 patients with valid data who received first-line treatment with bevacizumab and chemotherapy followed by aflibercept with chemotherapy. The majority of the patients (n = 296, 80.8%) had RAS mutated tumours. RESULTS: Median cumulative progression-free survival (PFS) from the start of the bevacizumab-containing regimen to progression on aflibercept was 18.2 months (95% CI 16.8-19.5). Median PFS for bevacizumab and aflibercept was 10.6 months (95% CI 9.5-11.7) and 5.6 months (95% CI 5.1-6.1), respectively. Longer PFS on aflibercept was associated with metachronous metastatic disease and longer PFS on bevacizumab. Median overall survival (OS) from the start of first-line bevacizumab was 32.0 months (95% CI 26.6-37.5). The presence of metastatic disease at diagnosis was associated with worse OS. CONCLUSIONS: Patients treated with aflibercept in real-world clinical practice achieved similar survival outcomes as those treated within randomised trials. Cumulative survival data provide a benchmark for future studies and enable indirect comparisons with other treatment sequences used in mCRC.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20028342
- 003
- CZ-PrNML
- 005
- 20210121111753.0
- 007
- ta
- 008
- 210105s2020 fr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s11523-020-00705-1 $2 doi
- 035 __
- $a (PubMed)32052341
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a fr
- 100 1_
- $a Buchler, Tomas $u Department of Oncology, First Faculty of Medicine, Charles University, Thomayer University Hospital, Videnska 800, 140 59, Prague, Czech Republic. tomas.buchler@ftn.cz.
- 245 10
- $a Sequential Treatment with Bevacizumab and Aflibercept for Metastatic Colorectal Cancer in Real-World Clinical Practice / $c T. Buchler, I. Kiss, J. Hornova, O. Fiala, M. Wiesnerova, M. Svoboda, J. Silar, K. Kopeckova, A. Poprach, J. Finek, L. Petruzelka, B. Melichar,
- 520 9_
- $a BACKGROUND: Bevacizumab and aflibercept are currently the mainstay of antiangiogenic therapy for metastatic colorectal carcinoma (mCRC). They are often used in sequence with first- and second-line chemotherapy, especially in patients with RAS-mutated tumours. OBJECTIVE: The aim of the present study was to investigate the outcomes of patients with mCRC treated with the bevacizumab-aflibercept sequence in real-world clinical practice. PATIENTS AND METHODS: Data from a national clinical registry of targeted therapies for mCRC were analysed retrospectively. Overall, there were 366 patients with valid data who received first-line treatment with bevacizumab and chemotherapy followed by aflibercept with chemotherapy. The majority of the patients (n = 296, 80.8%) had RAS mutated tumours. RESULTS: Median cumulative progression-free survival (PFS) from the start of the bevacizumab-containing regimen to progression on aflibercept was 18.2 months (95% CI 16.8-19.5). Median PFS for bevacizumab and aflibercept was 10.6 months (95% CI 9.5-11.7) and 5.6 months (95% CI 5.1-6.1), respectively. Longer PFS on aflibercept was associated with metachronous metastatic disease and longer PFS on bevacizumab. Median overall survival (OS) from the start of first-line bevacizumab was 32.0 months (95% CI 26.6-37.5). The presence of metastatic disease at diagnosis was associated with worse OS. CONCLUSIONS: Patients treated with aflibercept in real-world clinical practice achieved similar survival outcomes as those treated within randomised trials. Cumulative survival data provide a benchmark for future studies and enable indirect comparisons with other treatment sequences used in mCRC.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x farmakologie $x terapeutické užití $7 D000971
- 650 _2
- $a bevacizumab $x farmakologie $x terapeutické užití $7 D000068258
- 650 _2
- $a kolorektální nádory $x farmakoterapie $7 D015179
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a metastázy nádorů $7 D009362
- 650 _2
- $a doba přežití bez progrese choroby $7 D000077982
- 650 _2
- $a receptory vaskulárního endoteliálního růstového faktoru $x terapeutické užití $7 D040262
- 650 _2
- $a rekombinantní fúzní proteiny $x farmakologie $x terapeutické užití $7 D011993
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Kiss, Igor $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk Memorial Cancer Institute, Masaryk University, Zluty Kopec 543/7, 656 53, Brno, Czech Republic.
- 700 1_
- $a Hornova, Jana $u Department of Oncology, First Faculty of Medicine, Charles University, Thomayer University Hospital, Videnska 800, 140 59, Prague, Czech Republic.
- 700 1_
- $a Fiala, Ondrej $u Department of Oncology and Radiotherapeutics, University Hospital in Pilsen, Alej Svobody 80, 304 60, Pilsen, Czech Republic. Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 76, 323 00, Pilsen, Czech Republic.
- 700 1_
- $a Wiesnerová, Markéta $u Institute of Biostatistics and Analyses, Poštovská 68/3, 602 00, Brno, Czech Republic. $7 _AN108858
- 700 1_
- $a Svoboda, Michal $u Institute of Biostatistics and Analyses, Poštovská 68/3, 602 00, Brno, Czech Republic.
- 700 1_
- $a Silar, Jiri $u Institute of Biostatistics and Analyses, Poštovská 68/3, 602 00, Brno, Czech Republic.
- 700 1_
- $a Kopeckova, Katerina $u Department of Oncology, Motol University Hospital, Second Faculty of Medicine, Charles University, V Uvalu 84, 150 00, Prague, Czech Republic.
- 700 1_
- $a Poprach, Alexandr $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk Memorial Cancer Institute, Masaryk University, Zluty Kopec 543/7, 656 53, Brno, Czech Republic.
- 700 1_
- $a Finek, Jindrich $u Department of Oncology and Radiotherapeutics, University Hospital in Pilsen, Alej Svobody 80, 304 60, Pilsen, Czech Republic.
- 700 1_
- $a Petruzelka, Lubos $u Department of Oncology, General University Hospital, Charles University First Faculty of Medicine, U Nemocnice 499/2, 128 08, Prague, Czech Republic.
- 700 1_
- $a Melichar, Bohuslav $u Department of Oncology, Palacky University Medical School and Teaching Hospital, I.P. Pavlova 6, 775 20, Olomouc, Czech Republic.
- 773 0_
- $w MED00189571 $t Targeted oncology $x 1776-260X $g Roč. 15, č. 2 (2020), s. 193-201
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32052341 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20210105 $b ABA008
- 991 __
- $a 20210121111752 $b ABA008
- 999 __
- $a ok $b bmc $g 1608677 $s 1119522
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 15 $c 2 $d 193-201 $e - $i 1776-260X $m Targeted oncology $n Target Oncol $x MED00189571
- LZP __
- $a Pubmed-20210105
